AIMS: Because low-grade inflammation may play a role in the pathogenesis of coronary heart disease (CHD), and pro-inflammatory cytokines govern inflammatory cascades, this study aimed to assess the associations of several pro-inflammatory cytokines and CHD risk in a new prospective study, including meta-analysis of prospective studies. METHODS AND RESULTS: Interleukin-6 (IL-6), IL-18, matrix metalloproteinase-9 (MMP-9), soluble CD40 ligand (sCD40L), and tumour necrosis factor-α (TNF-α) were measured at baseline in a case-cohort study of 1514 participants and 833 incident CHD events within population-based prospective cohorts at the Danish Research Centre for Prevention and Health. Age- and sex-adjusted hazard ratios (HRs) for CHD per 1-SD higher log-transformed baseline levels were: 1.37 (95% CI: 1.21-1.54) for IL-6, 1.26 (1.11-1.44) for IL-18, 1.30 (1.16-1.46) for MMP-9, 1.01 (0.89-1.15) for sCD40L, and 1.13 (1.01-1.27) for TNF-α. Multivariable adjustment for conventional vascular risk factors attenuated the HRs to: 1.26 (1.08-1.46) for IL-6, 1.12 (0.95-1.31) for IL-18, 1.21 (1.05-1.39) for MMP-9, 0.93 (0.78-1.11) for sCD40L, and 1.14 (1.00-1.31) for TNF-α. In meta-analysis of up to 29 population-based prospective studies, adjusted relative risks for non-fatal MI or CHD death per 1-SD higher levels were: 1.25 (1.19-1.32) for IL-6; 1.13 (1.05-1.20) for IL-18; 1.07 (0.97-1.19) for MMP-9; 1.07 (0.95-1.21) for sCD40L; and 1.17 (1.09-1.25) for TNF-α. CONCLUSIONS: Several different pro-inflammatory cytokines are each associated with CHD risk independent of conventional risk factors and in an approximately log-linear manner. The findings lend support to the inflammation hypothesis in vascular disease, but further studies are needed to assess causality.
AIMS: Because low-grade inflammation may play a role in the pathogenesis of coronary heart disease (CHD), and pro-inflammatory cytokines govern inflammatory cascades, this study aimed to assess the associations of several pro-inflammatory cytokines and CHD risk in a new prospective study, including meta-analysis of prospective studies. METHODS AND RESULTS: Interleukin-6 (IL-6), IL-18, matrix metalloproteinase-9 (MMP-9), soluble CD40 ligand (sCD40L), and tumour necrosis factor-α (TNF-α) were measured at baseline in a case-cohort study of 1514 participants and 833 incident CHD events within population-based prospective cohorts at the Danish Research Centre for Prevention and Health. Age- and sex-adjusted hazard ratios (HRs) for CHD per 1-SD higher log-transformed baseline levels were: 1.37 (95% CI: 1.21-1.54) for IL-6, 1.26 (1.11-1.44) for IL-18, 1.30 (1.16-1.46) for MMP-9, 1.01 (0.89-1.15) for sCD40L, and 1.13 (1.01-1.27) for TNF-α. Multivariable adjustment for conventional vascular risk factors attenuated the HRs to: 1.26 (1.08-1.46) for IL-6, 1.12 (0.95-1.31) for IL-18, 1.21 (1.05-1.39) for MMP-9, 0.93 (0.78-1.11) for sCD40L, and 1.14 (1.00-1.31) for TNF-α. In meta-analysis of up to 29 population-based prospective studies, adjusted relative risks for non-fatal MI or CHD death per 1-SD higher levels were: 1.25 (1.19-1.32) for IL-6; 1.13 (1.05-1.20) for IL-18; 1.07 (0.97-1.19) for MMP-9; 1.07 (0.95-1.21) for sCD40L; and 1.17 (1.09-1.25) for TNF-α. CONCLUSIONS: Several different pro-inflammatory cytokines are each associated with CHD risk independent of conventional risk factors and in an approximately log-linear manner. The findings lend support to the inflammation hypothesis in vascular disease, but further studies are needed to assess causality.
Authors: Bernard Keavney; John Danesh; Sarah Parish; Alison Palmer; Sarah Clark; Linda Youngman; Marc Delépine; Mark Lathrop; Richard Peto; Rory Collins Journal: Int J Epidemiol Date: 2006-07-26 Impact factor: 7.196
Authors: John Danesh; Stephen Kaptoge; Andrea G Mann; Nadeem Sarwar; Angela Wood; Sara B Angleman; Frances Wensley; Julian P T Higgins; Lucy Lennon; Gudny Eiriksdottir; Ann Rumley; Peter H Whincup; Gordon D O Lowe; Vilmundur Gudnason Journal: PLoS Med Date: 2008-04-08 Impact factor: 11.069
Authors: Frances Wensley; Pei Gao; Stephen Burgess; Stephen Kaptoge; Emanuele Di Angelantonio; Tina Shah; James C Engert; Robert Clarke; George Davey-Smith; Børge G Nordestgaard; Danish Saleheen; Nilesh J Samani; Manjinder Sandhu; Sonia Anand; Mark B Pepys; Liam Smeeth; John Whittaker; Juan Pablo Casas; Simon G Thompson; Aroon D Hingorani; John Danesh Journal: BMJ Date: 2011-02-15
Authors: Heather M Derry; Avelina C Padin; Jennifer L Kuo; Spenser Hughes; Janice K Kiecolt-Glaser Journal: Curr Psychiatry Rep Date: 2015-10 Impact factor: 5.285
Authors: Raffaele Altara; Marco Manca; Marleen H Hessel; Yumei Gu; Laura C van Vark; K Martijn Akkerhuis; Jan A Staessen; Harry A J Struijker-Boudier; George W Booz; W Matthijs Blankesteijn Journal: J Cardiovasc Transl Res Date: 2016-06-06 Impact factor: 4.132
Authors: Dilorom M Djalilova; Paula S Schulz; Ann M Berger; Adam J Case; Kevin A Kupzyk; Alyson C Ross Journal: Biol Res Nurs Date: 2018-12-20 Impact factor: 2.522
Authors: Mohammad Raish; Ajaz Ahmad; Mushtaq Ahmad Ansari; Khalid M Alkharfy; Abdul Ahad; Altaf Khan; Naushad Ali; Majid A Ganaie; Mohammed Abbas Ali Hamidaddin Journal: 3 Biotech Date: 2019-03-23 Impact factor: 2.406
Authors: Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo Journal: Mol Med Date: 2014-06-12 Impact factor: 6.354
Authors: Roland von Känel; Paul J Mills; Joel E Dimsdale; Michael G Ziegler; Matthew A Allison; Thomas L Patterson; Sonia Ancoli-Israel; Christopher Pruitt; Igor Grant; Brent T Mausbach Journal: J Gerontol A Biol Sci Med Sci Date: 2020-10-15 Impact factor: 6.053